CITY Trial Supports Use of CGM in Adolescents with Type 1 Diabetes

The CITY trial tested whether the Dexcom G5 continuous glucose monitor (CGM) could improve outcomes in adolescents (14-25 years) with type 1 diabetes. Compared to BGM,

CGM resulted in a 4 mmol per mol greater reduction in A1C ­after six months – impressive given that meeting A1C goals is particularly difficult in this teenage age group. The average starting A1C was 8.9%, extremely high

Those on CGM also experienced 1.4 hours per day more in-range (4-10 mmol/l), slightly less time spent above 10 mmol/l, 58% vs. 54% of the day, and less time spent below 3,9 mmol/l, 3.2% vs. 2.2%. It’s an hour less time high a day, and 15 minutes less time low a day - that is much.

While these results are exciting, Dr. Lori Laffel of the Joslin Diabetes Center emphasized that time spent above 10  mmol/l still comprised over half the day, indicating that more work needs to be done.

Encouragingly, good news came from the user reports, which detailed more life satisfaction with CGM than BGM and greater perceived benefits of CGM, to name a few.

We’re also happy to see that there were no differences in diabetes distress or sleep quality between the CGM and BGM groups – a concern due to CGM alarms.

Participants from both groups are currently being followed for an additional six months using the Dexcom G6. This is such exciting research and we’re thrilled at these outcomes. 




www red DiabetologNytt